

Product datasheet for **TR301215**

TAZ Human shRNA Plasmid Kit (Locus ID 6901)

Product data:

Product Type:	shRNA Plasmids
Product Name:	TAZ Human shRNA Plasmid Kit (Locus ID 6901)
Locus ID:	6901
Synonyms:	BTHS; CMD3A; EFE; EFE2; G4.5; LVNCX; TAZ; Taz1
Vector:	pRS (TR20003)
E. coli Selection:	Ampicillin
Mammalian Cell Selection:	Puromycin
Format:	Retroviral plasmids
Components:	TAZ - Human, 4 unique 29mer shRNA constructs in retroviral untagged vector(Gene ID = 6901). 5µg purified plasmid DNA per construct 29-mer scrambled shRNA cassette in pRS Vector, TR30012, included for free.
RefSeq:	NM_000116 , NM_001303465 , NM_181311 , NM_181312 , NM_181313 , NM_181314 , NR_024048 , NM_181311.2 , NM_181311.3 , NM_000116.1 , NM_000116.2 , NM_000116.3 , NM_000116.4 , NM_181312.1 , NM_181312.3 , NM_181313.1 , NM_181313.2 , NM_181313.3 , NM_181314.1 , BC005062 , BC011515 , NM_181313.4 , NM_000116.5 , NM_181311.4 , NM_181312.4
UniProt ID:	Q16635
Summary:	This gene encodes a protein that is expressed at high levels in cardiac and skeletal muscle. Mutations in this gene have been associated with a number of clinical disorders including Barth syndrome, dilated cardiomyopathy (DCM), hypertrophic DCM, endocardial fibroelastosis, and left ventricular noncompaction (LVNC). Multiple transcript variants encoding different isoforms have been described. A long form and a short form of each of these isoforms is produced; the short form lacks a hydrophobic leader sequence and may exist as a cytoplasmic protein rather than being membrane-bound. Other alternatively spliced transcripts have been described but the full-length nature of all these transcripts is not known. [provided by RefSeq, Jul 2008]
shRNA Design:	These shRNA constructs were designed against multiple splice variants at this gene locus. To be certain that your variant of interest is targeted, please contact techsupport@origene.com . If you need a special design or shRNA sequence, please utilize our custom shRNA service .



[View online »](#)

**Performance
Guaranteed:**

OriGene guarantees that the sequences in the shRNA expression cassettes are verified to correspond to the target gene with 100% identity. One of the four constructs at minimum are guaranteed to produce 70% or more gene expression knock-down provided a minimum transfection efficiency of 80% is achieved. Western Blot data is recommended over qPCR to evaluate the silencing effect of the shRNA constructs 72 hrs post transfection. To properly assess knockdown, the gene expression level from the included scramble control vector must be used in comparison with the target-specific shRNA transfected samples.

For non-conforming shRNA, requests for replacement product must be made within ninety (90) days from the date of delivery of the shRNA kit. To arrange for a free replacement with newly designed constructs, please contact Technical Services at techsupport@origene.com. Please provide your data indicating the transfection efficiency and measurement of gene expression knockdown compared to the scrambled shRNA control (Western Blot data preferred).